Virobay Facts

2014 – Virobay appoints Thomas J. Dietz, Ph.D. to the Virobay Board of Directors more

2013 – Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain more

2013 – Virobay and LEO Pharma initiate a Phase 1 Trial of VBY-891, a compound intended for oral treatment of psoriasis more

2012 – Virobay's Cathepsin S selected as one of the Top 10 Anti-Inflammatory/Autoimmune Projects to Watch more

2012 – LEO Pharma A/S has entered into a multi-million dollar collaboration with Virobay Inc. to develop an oral treatment for psoriasis more

2010 – Virobay closes Series B financing

2008 – Virobay assets solve the chemical challenge of cathepsin inhibitor design; multiple development candidates are poised for Phase I

2007 – In-licensed cathepsin protease inhibitor assets

2007 – Filed IND and initiated Phase I trial with lead protease inhibitor as an oral treatment for Hepatitis C

2006 – Founded as a protease inhibitor drug discovery and development company

more

News

December 5, 2012

Cathepsin S, Virobay’s lead drug candidate, was selected by Windhover as one of the top 10 most interesting inflammatory/autoimmune projects available for partnering.

"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees considered the most attractive anti-inflammatory/autoimmune opportunities the industry has to offer," said David Cassak, Vice President, Content, Windhover Conferences, a division of Elsevier Business Intelligence.

"Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability."

Link to presentation "Cathepsin S Inhibitors for the Treatment of Inflammatory Bowel Disease"